We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this free, full length talk
Topics Covered
- Current knowledge of the immune response to SARS-CoV-2
- Involvement of the T cell response
- Testing and detecting the antibody and T cell response
- Hypotheses on the range of responses to the virus
- Future steps
Biography
Paul Klenerman trained in medicine at Cambridge and Oxford and specialised in infectious diseases. He did his PhD in viral immunology at Oxford University and a postdoc in Zurich before returning to Oxford to establish a lab looking at immune responses to infection. The work includes studies of hepatitis C and a range of viruses affecting the lungs and liver - looking at how these evade the immune response, and the development of vaccines. He is focused especially on novel T cell responses in the mucosal surfaces which are critical for early host defence. He is an NIHR senior fellow and a Wellcome Trust investigator and holds a chair in the Nuffield Department of Medicine in Oxford.
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Klenerman, P. (2020, July 9). The immune system response to the SARS-CoV-2 virus: July 2020 update [Audio file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 5, 2023, from https://hstalks.com/bs/4344/.Export Citation (RIS)
Publication History
Financial Disclosures
- There are no commercial/financial matters to disclose.
Other Talks in the Playlist: Interviews on Covid-19
Transcript
Please wait while the transcript is being prepared...
0:00
Interviewer: Professor Klenerman,
thank you for
taking the time to record this
update on what we now know
about the immune system response
to the SARS-CoV-2 virus.
What are some of the key points which have
been found in the immune system response
in COVID-19 infection
since your last interview?
Prof Klenerman: Hi, if we split
the immune response into two, so
the antibody response, and
the cellular immune response or
the T-cell response,
then maybe I'll address those in turn.
In terms of the antibody response it's
been an enormous effort to create tests
which can pick up antibodies.
People have been using those quite widely,
and the very first ones that came out at
the beginning, some of the stick-tests
were not very sensitive, and
people have worked hard
to improve on that.
So lots of different labs have created
individual assays, which allow people to
measure whether you've made antibodies
against particularly the spike-protein,
which is the big protein that
allows the virus to enter cells.
And those actually work very well in
individual labs, but there's always
an additional complication in trying to
make these into essentially a clinical
tool so that they work day in day out,
the same in every lab in the globe.
I think though it looks as if different
companies have created different
versions of a test, which all
actually perform reasonably well.
I mean, there will be small
differences between them, but
fundamentally they can
measure an immune response.
The difficulty for all the tests is,
what's the cut off?
That's much harder for
this virus than others,
because there is quite
a wide range of responses.